You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Colorcon
Moodys
Express Scripts
McKinsey

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,877,708

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,877,708 protect, and when does it expire?

Patent 8,877,708 protects CYCLOSET and is included in one NDA.

This patent has ten patent family members in seven countries.

Summary for Patent: 8,877,708
Title:Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI)
Assignee: VeroScience, LLC (Tiverton, RI)
Application Number:13/375,810
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,877,708

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,877,708

PCT Information
PCT FiledJune 07, 2010PCT Application Number:PCT/US2010/037605
PCT Publication Date:December 09, 2010PCT Publication Number: WO2010/141938

International Family Members for US Patent 8,877,708

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010256366   Start Trial
Brazil PI1009619   Start Trial
China 102458376   Start Trial
European Patent Office 2437732   Start Trial
European Patent Office 3375437   Start Trial
Spain 2682644   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Johnson and Johnson
AstraZeneca
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.